Boehringer Ingelheim’s OFEV capsules receive FDA acceptance for IPF treatment Boehringer Ingelheim Pharmaceuticals, Inc. Announced that the U today viagra virkning .S. Granted Breakthrough Therapy designation during its review by the FDA, OFEV, capsules for oral make use of, taken twice daily, may be the just kinase inhibitor authorized to treat IPF. OFEV will be accessible to patients within 10 days. IPF is a uncommon and fatal lung disease that affects as much as 132,000 Americans. A lot of people with IPF just live 3 to 5 years after analysis. As the reason behind IPF is unfamiliar and there is absolutely no known curative treatment, the unfortunate sufferers confronted with the condition and physicians looking after sufferers in the U.S.